There is an impending shortage of antibiotics to combat emerging resistant infections. The antibiotic pipeline has been regulated to death, so says a commentary from last May in the Washington Times.
Marketing considerations and regulatory costs have exacerbated the antibiotics drought. Until about a decade ago, all major pharmaceutical makers had antibacterial research programs, but they have dramatically trimmed or eliminated these efforts, focusing instead on more lucrative drugs that treat chronic ailments and lifestyle issues. Read the rest.
I previously cited the Infectious Disease Society of America’s warning here.